Newsbenzinga
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection
· Published
Article summary
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
An excerpt from the original article.
Comments —
Loading comments…